Background

Ascertaining pregnancy location is the key determinant for streamlining management for patients presenting with abdominal pain or bleeding in early pregnancy. However, sometimes, efforts to find the location of gestation sac can be difficult and such cases have been classified as Pregnancy of Unknown Location (PUL). The lack of an acceptable definition and diagnostic criteria for PUL is reflected by differences in the management strategies of PUL. As locating early pregnancy is dependent on many factors, incidence of PUL may vary in different settings. According to recent reports, Specialist units have reported that PUL is diagnosed in 8-10% vs 8-31% in non-specialist units [1]. PUL outcome data is very encouraging from hospitals that have used clear PUL care pathways in incorporating reliable diagnostic criteria. Only few UK units have opted their PUL management based on a clear predictive tool including widely accepted hormone tests. Hence we conducted a prospective study to review the PUL managed cases and aimed to propose a new local protocol for diagnosing and managing atypical presentations aiming to achieve outcome in 5 to 9 days durations.

Aim

The aim was to find out the timeline for diagnosis and outcome of PUL cases and the requirement of scans and βHCG tests. Also wanted to find out the pattern and frequency of scans and βHCG in PUL cases.

Criteria

PUL cases were identified if there was no evidence of intrauterine or extra-uterine pregnancy on first transvaginal ultrasound scan (5-6 week gestation) in women with a positive pregnancy test.

Methods

This was a prospective observational study, including all patients attending EGAU (Early Gynaecology Assessment Unit) who were diagnosed as PUL between January 2015 and January 2016. PUL outcome data was very encouraging from hospitals that have used clear PUL care pathways in incorporating reliable diagnostic criteria. Only few UK units have opted their PUL management based on a clear predictive tool including widely accepted hormone tests. Hence we conducted a prospective study to review the PUL managed cases and aimed to propose a PUL management pathway and thereby reducing variation.

Result

Fifty patients who attended EGAU were included in this PUL study. Six patients were excluded as they didn’t meet the criteria of PUL study protocol. The 28% (n=14) found to have intra-
Pregnancy of Un-Known Location: Need for Evolving New Protocols and Evaluation of Tools for Increasing Outcome Predictability

The suboptimal βHCG rise was seen in 11% (n=5) patients, who later were diagnosed with ectopic pregnancy. The remaining 56% (n=25 / 44) patients failing IUP and none of them were labelled as persistent PUL (Figure 1). The serum βHCG assessments were undertaken 3-8 times before reaching diagnosis in Ectopic group whereas in Failing IUP group serum βHCG was done 2-6 times and in IUP cohort it remained one to two tests. Our data revealed that number of scans required for each patient in above mentioned three groups varied. For ectopic group patients had 2- 4 scans, and patients in failing IUP & IUP group required an average 1-3 pelvic scans (Table 1). In cases which required more than three βHCG the management was discussed with consultant on call for further follow up. The analysis of ectopic pregnancy group revealed that suboptimal rise in serum βHCG and ultrasound scan findings were the main factors considered leading to the diagnosis of ectopic. All patients in ectopic group remained hemodynamically stable. The mean time to establish diagnosis in ectopic group was 6-21 days, and serum βHCG discriminatory zone values ranged (1500- 2400 IU/L). One case diagnosed as ectopic pregnancy on 21st day of reporting EGAU, while the serum βHCG values were <1500IU/L.

Table 1: Frequency of βHCG and Transvaginal ultrasound scans in each patient.

<table>
<thead>
<tr>
<th>Outcome Group</th>
<th>No. Scans Per Patient</th>
<th>No. of βHCG per Patient</th>
<th>Mean Time of Diagnosis Established (Days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Failing Pregnancy</td>
<td>1-3</td>
<td>2-6</td>
<td>2-32</td>
</tr>
<tr>
<td>Ectopic</td>
<td>2-4</td>
<td>3-8</td>
<td>6-21</td>
</tr>
<tr>
<td>IUP</td>
<td>1-2</td>
<td>1-2</td>
<td>2-14</td>
</tr>
</tbody>
</table>

Discussion

The term ‘Pregnancy of Unknown Location’ (PUL) is referred when there is no conclusive evidence of either intra- or extra uterine pregnancy or retained products of conception on transvaginal ultrasound, despite a positive pregnancy test [2]. The issue with PUL are as below

i. Overtreatment in the form of early laparoscopy since there is false negative rate of 3-4% when undertaken done too early and 5% false positive rate of laparoscopy are due to the presence of retrograde uterine bleeding in miscarriage which can be misinterpreted as tubal ectopic pregnancy.

ii. Fear of missing Ectopic pregnancy with "Wait & see conservative policy".

iii. No clear defined role of methotrexate in PUL cases and concern of using in early pregnancy of uncertain viability.

iv. Multiple follow ups with Blood (BHCG, Progesterone) investigation with not well-established predictive value.

v. Repeated ultrasound scans follow up and issues with reporting and expertise in specialised versus non specialised units.

Less consistency in scan report quality in non-specialist unit has been recognised as an issue. This trend was seen in our study as well requiring up to four scan in some patients of ectopic group and three scans in failing IUP group. As there are still no conclusive RCT (randomised controlled trials) published to compare different management strategies for PUL. There seemed a clinical heterogeneity between the studied populations; highlights to revisit the policy to adhere to specific models extrapolated from studies conducted in relatively bigger specialist units where possible best expertise and equipment are available. It is rather advisable to develop management PUL protocol locally; taking into the consideration demographics of population and available facilities and expertise. We proposed a new protocol shown below based on findings from our study (Figure 2). This pathway B & C (Figure 2) follows the same flow as per NICE Assessment of pregnancy of un known location interactive flow chart [3] but differs from point A to further into A1, A2 and A3. It can be argued that setting a target (time limit) to reach definitive diagnosis may not be achievable in all patients but in new proposed protocol total duration from initial presentation to final treatment offered will be 9,7 and 5 days in Pathway A1, A2 and A3 respectively ( fig 2 ) on contrary to initial finding of diagnosis of 2-32 days for failing pregnancy and ranged between 6-21 days for ectopic pregnancy.

There are number of different models designed to define and classify PUL management based on various mathematical calculations, including βHCG with or without progesterone levels. Two protocols seemed more pragmatic to implement safely in our unit for the prediction of failing group and early intrauterine pregnancy group.

Model 1

One was proposed by Condous et al. (4) that the serum βHCG ratio at 48hr: 0hr <0.87 promises an optimal test for the prediction of failing pregnancy. It was concluded from our study that serum βHCG ratio <0.87 (Table 2) can easily and safely be used for predicting failing pregnancy in PUL cases (>50%).
Table 2: Validity of \( \beta \text{HCG} \) level ratio \( @ \, 48 \, \text{h}/0 \, <0.87 \) as predictive tool for failing pregnancy.

<table>
<thead>
<tr>
<th>BHCG 48hr/0 hr Ratio</th>
<th>Number of Cases out of Total Failing Pregnancy Group (n/25)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of cases (n) in failing pregnancy group where BHCG ratio was &lt;0.87</td>
<td>14/25 (56%)</td>
</tr>
<tr>
<td>Number of cases (n) in failing pregnancy group where BHCG ratio was &gt;0.87</td>
<td>10/25 (40%)</td>
</tr>
</tbody>
</table>

Model 2

The other model was suggested by Bignardi T et al. (5) who concluded that \( \beta \text{HCG} \) ratio \( 48\text{hr}/0\text{hr} >2.00 \) points toward increased chances for a viable IUP and our study proved that serum \( \beta \text{HCG} \) ratio >2.0 (Table 3) can be helpful in predicting ongoing early intrauterine pregnancy in PUL cases (>60%).

Table 3: Validity of \( \beta \text{HCG} \) level ratio \( @ \, 48\text{h}/0\text{h} >2.00 \) as predictive tool for a viable Intrauterine pregnancy (IUP).

<table>
<thead>
<tr>
<th>( \beta \text{HCG} ) 48hr/0 hr Ratio</th>
<th>Number of Cases out of Total IUP Group (n/25)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of cases (n) in early IUP group where ( \beta \text{HCG} ) ratio was &gt;2</td>
<td>9/14 (64%)</td>
</tr>
<tr>
<td>Number of cases (n) in early IUP group where ( \beta \text{HCG} ) ratio was &gt; 1.6-2</td>
<td>5/14 (35%)</td>
</tr>
</tbody>
</table>

Strengths and Limitations

This was a small but prospective study conducted in District General Hospital but a sample size of more than 40 was taken to ensure that the sample mean is approximately normally distributed. All proformas were collectively analysed at the end of study to reduce the risk of bias and influence on management during the study period. The inferences drawn from this study may not be applicable nationally for National guidelines but hopefully smaller early pregnancy assessment units may benefit from finding of our study in developing and testing new departmental protocols.

Conclusion

To reach the final definite diagnosis / outcome in PUL cases in set time limit it may not be possible in some atypical presentation of early pregnancy problems especially when the aim is to avoid unnecessary scans, follow ups and blood test without compromising the safety. Therefore we suggested a protocol for diagnosing and managing atypical presentations of PUL.

Recommendation

i. Introduction of local pathways where initial presentation to final treatment will be offered 9 days (serum \( \beta \text{HCG} \) <500IU/L group), 7 days (serum \( \beta \text{HCG} \) 500-1000IU/L group) and 5 days where BHCG will be > 1000IU/L. It may help reducing unnecessary follow ups and may streamline management of difficult scenarios of plateauing serum \( \beta \text{HCG} \).

ii. Audit in a year’s time to review the results to ensure safety.

iii. Use of methotrexate in selective hemodynamically stable patients as per NICE guideline [6] after counselling and careful consideration that possibility of early viable pregnancy is ruled out.

Authors Contribution

a) JR designed and conducted the study and did manuscript writing.

b) HK did editing manuscript, review and final approval of manuscript.

c) GM Collected data with JR and helped writing manuscript.

Conflict of Interest

None.

References


3. NICE Assessment of pregnancy of unknown location interactive flow chart.

